Completed PHASE1 INTERVENTIONAL 2-arm NCT00364676

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

A Phase 1 Study of Vinorelbine Liposomes Injection (VLI) for Treatment in Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Sponsor: Spectrum Pharmaceuticals, Inc

Conditions Hodgkins Disease Non-Hodgkins Lymphoma Tumors

Interventions VLI

Updated 6 times since 2017 Last updated: Sep 18, 2015 Started: Jul 31, 2006 Primary completion: Jun 30, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00364676, this PHASE1 trial focuses on Hodgkins Disease and Non-Hodgkins Lymphoma and remains completed. Sponsored by Spectrum Pharmaceuticals, Inc, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Spectrum Pharmaceuticals, Inc

Data source: Spectrum Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada
• San Antonio, United States